The primary objective is to compare the efficacy of SM-13496 (20-60 or 80-120 mg/day) monotherapy with that of placebo in patients with depressive symptoms associated with bipolar I disorder by assessing the change from baseline in the MADRS total score at Week 6.
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.